Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

, PFE

Pfizer

$36.27

-0.06 (-0.17%)

22:34
03/21/18
03/21
22:34
03/21/18
22:34

GlaxoSmithKline in lead to buy Pfizer consumer unit, FT says

With Reckitt Benckiser (RBGLY) already having confirmed it is out of the bidding for Pfizer's (PFE) Consumer Healthcare unit, stating that an acquisition for the whole business "did not fit" its acquisition criteria and an acquisition of part of the business "was not possible," GlaxoSmithKline (GSK) is in pole position to buy the owner of the Advil and Centrum brands, according to Financial Times. Pfizer has said it was considering a sale or spinoff of the business, or it could still decide to keep the division, the report added. Reference Link

GSK

GlaxoSmithKline

PFE

Pfizer

$36.27

-0.06 (-0.17%)

RBGLY

Reckitt Benckiser

$16.14

0.18 (1.13%)

  • 25

    Mar

  • 04

    Apr

  • 23

    Apr

GSK GlaxoSmithKline

01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
02/22/18
LEER
02/22/18
NO CHANGE
LEER
Rapid adoption of Gilead Biktarvy to challenge GlaxoSmithKline outlook, says Leerink
Leerink analyst Seamus Fernandez notes he has recently completed a MEDACorp survey of U.S. HIV treatment specialists and has found "impressively positive" sentiment about Gilead's (GILD) Biktarvy which seems likely to put sustained pressure on GlaxoSmithKline's (GSK) leading integrase inhibitor Tivicay, as well as cannibalizing Gilead's other combination and component products.
PFE Pfizer
$36.27

-0.06 (-0.17%)

12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
02/07/18
HCWC
02/07/18
NO CHANGE
Target $31
HCWC
Buy
Achaogen price target raised to $31 from $25 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $78
SBSH
Buy
Three developments make Pfizer buying Bristol-Myers more likely, says Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares.
RBGLY Reckitt Benckiser
$16.14

0.18 (1.13%)

07/06/17
JEFF
07/06/17
DOWNGRADE
JEFF
Hold
Reckitt Benckiser downgraded to Hold from Buy at Jefferies
Jefferies analyst Martin Deboo downgraded Reckitt Benckiser to Hold saying the recent share rally no longer leaves sufficient upside for a Buy rating. The analyst raised his price target to 8,400p from 7,750p.

TODAY'S FREE FLY STORIES

$DJT

DJ Transportation Average

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$30.48

-0.74 (-2.37%)

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Hot Stocks
Twitter says removed more than 142K apps violating TOS in Q1 »

In its Q1 letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

CR

Crane

$87.78

-7.56 (-7.93%)

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Upgrade
Crane rating change  »

Crane upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

GE

General Electric

$14.68

0.16 (1.10%)

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Hot Stocks
General Electric, U.S. Army conduct PDR for T901 engine »

GE Aviation hosted the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DJX

Dow Jones Industrial Average

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$187.07

-3.92 (-2.05%)

08:20
04/25/18
04/25
08:20
04/25/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
04/25/18
04/25
08:20
04/25/18
08:20
General news
U.S. equities remain on the defensive »

U.S. equities remain on…

ZGNX

Zogenix

$39.35

-0.65 (-1.63%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Hot Stocks
Zogenix announces new safety, efficacy data from Phase 3 clinical trial of ZX008 »

Zogenix announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$33.26

-0.58 (-1.71%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Upgrade
Noble Energy rating change  »

Noble Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 22

    May

XLK

Technology Select Sector SPDR

$64.83

-1.14 (-1.73%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.95

-0.8 (-1.08%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$101.56

-1.62 (-1.57%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYDS

Payment Data Systems

$1.68

0.04 (2.44%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Initiation
Payment Data Systems initiated  »

Payment Data Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSFL

CenterState Banks

$27.74

0.22 (0.80%)

, CHFN

Charter Financial

$21.62

-0.01 (-0.05%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Conference/Events
Charter Financial to host conference call »

Conference call to…

CSFL

CenterState Banks

$27.74

0.22 (0.80%)

CHFN

Charter Financial

$21.62

-0.01 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Sep

XLB

S&P Select Materials SPDR

$57.25

-1.57 (-2.67%)

08:19
04/25/18
04/25
08:19
04/25/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$221.23

-2.61 (-1.17%)

, AMD

AMD

$10.09

0.055 (0.55%)

08:18
04/25/18
04/25
08:18
04/25/18
08:18
Periodicals
Taiwan graphic card shipments in seen down 40% m/m in April, Digitimes says »

Taiwan-based graphics…

NVDA

Nvidia

$221.23

-2.61 (-1.17%)

AMD

AMD

$10.09

0.055 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 10

    May

BASFY

BASF

, GPS

Gap

$29.19

0.395 (1.37%)

08:18
04/25/18
04/25
08:18
04/25/18
08:18
Conference/Events
House Ways & Means Committee to hold a hearing »

The Committee holds a…

BASFY

BASF

GPS

Gap

$29.19

0.395 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$50.66

0.33 (0.66%)

08:18
04/25/18
04/25
08:18
04/25/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$50.13

-0.3 (-0.59%)

08:18
04/25/18
04/25
08:18
04/25/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$81.77

-0.65 (-0.79%)

08:18
04/25/18
04/25
08:18
04/25/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$154.43

-0.89 (-0.57%)

08:17
04/25/18
04/25
08:17
04/25/18
08:17
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USG

USG

$40.08

-0.52 (-1.28%)

08:17
04/25/18
04/25
08:17
04/25/18
08:17
Hot Stocks
USG says making strategic progress towards achieving 2020 financial targets »

On slides that will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

VLKAY

Volkswagen

08:17
04/25/18
04/25
08:17
04/25/18
08:17
Upgrade
Volkswagen rating change  »

Volkswagen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$41.50

1.06 (2.62%)

, AAPL

Apple

$162.87

-2.38 (-1.44%)

08:17
04/25/18
04/25
08:17
04/25/18
08:17
Recommendations
Teradyne, Apple analyst commentary  »

Apple fears appear to…

TER

Teradyne

$41.50

1.06 (2.62%)

AAPL

Apple

$162.87

-2.38 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 16

    May

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.